Ronan Martin Murphy Sells 5,005 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Ronan Murphy sold 5,005 shares of Icon stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $875,875.00. Following the transaction, the director directly owned 3,847 shares of the company’s stock, valued at approximately $673,225. This trade represents a 56.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ronan Martin Murphy also recently made the following trade(s):

• On Tuesday, August 11th, Ronan Murphy sold 841 shares of Icon stock. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89.

Icon Stock Down 2.4%

Shares of NASDAQ:ICLR opened at $169.68 on Friday. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91. The stock has a fifty day simple moving average of $167.27 and a two-hundred day simple moving average of $140.01. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $12.99 billion, a price-to-earnings ratio of 39.83, a PEG ratio of 8.03 and a beta of 1.20.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.26 earnings per share. On average, research analysts anticipate that Icon Plc will post 9.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ICLR shares. DA Davidson set a $164.00 target price on shares of Icon in a research note on Monday, June 1st. Jefferies Financial Group restated a “buy” rating and issued a $165.00 price objective on shares of Icon in a research report on Friday, May 29th. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. TD Cowen upped their price target on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Icon in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $170.40.

Institutional Investors Weigh In On Icon

Hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP purchased a new position in shares of Icon in the 2nd quarter worth $594,000. Baird Financial Group Inc. purchased a new position in Icon in the second quarter worth about $376,000. Parkside Financial Bank & Trust increased its stake in Icon by 120.0% during the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company’s stock worth $107,000 after acquiring an additional 336 shares during the last quarter. VELA Investment Management LLC raised its position in Icon by 511.4% during the second quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company’s stock valued at $2,118,000 after purchasing an additional 10,198 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in Icon during the second quarter valued at approximately $6,337,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Company Profile

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.